Apraclonidine

Apraclonidine
Clinical data
Trade names	Iopidine
AHFS/Drugs.com	Monograph
MedlinePlus	a608005
Routes of; administration	Topical (ophthalmic solution)
ATC code	S01EA03 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	98.7%
Elimination half-life	8 hours
Identifiers
	IUPAC name 2,6-Dichloro-N- (4,5-dihydro-1H-imidazol-2-yl) benzene-1,4-diamine;
CAS Number	66711-21-5 ;
PubChem CID	2216;
IUPHAR/BPS	7117;
DrugBank	DB00964 ;
ChemSpider	2130 ;
UNII	843CEN85DI;
KEGG	D07461 ;
ChEBI	CHEBI:2788 ;
ChEMBL	ChEMBL647 ;
CompTox Dashboard (EPA)	DTXSID1048415 ;
ECHA InfoCard	100.164.104
Chemical and physical data
Formula	C9H10Cl2N4
Molar mass	245.11 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1c(c(Cl)cc(N)c1)N/C2=N/CCN2;
	InChI InChI=1S/C9H10Cl2N4/c10-6-3-5(12)4-7(11)8(6)15-9-13-1-2-14-9/h3-4H,1-2,12H2,(H2,13,14,15) ; Key:IEJXVRYNEISIKR-UHFFFAOYSA-N ;
	(verify)

Apraclonidine (INN), also known under the brand name Iopidine, is a sympathomimetic used in glaucoma therapy. It is an α₂ adrenergic receptor agonist and a weak α₁ adrenergic receptor agonist.^{[citation needed]}

Topical apraclonidine is administered at a concentration of 1% for the prevention and treatment of post-surgical intraocular pressure (IOP) elevation and 0.5% for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional reduction of IOP. One drop is usually added one hour prior to laser eye surgery and another drop is given after the procedure is complete.